U.S. Precision Medicine
U.S. Precision Medicine (USPM) is developing DH20931, an AI-accelerated drug candidate targeting CerS2 for cancer therapeutics. With demonstrated 85% tumor reduction in preclinical trials, DH20931 aims to revolutionize oncology treatment by selectively inducing apoptosis in cancer cells. The company operates in the $200 billion global oncology market and holds patent protection until 2044. USPM leverages a proprietary drug discovery approach enhanced by AI collaborations and strategic partnerships with research institutions to address unmet needs in cancer treatment, positioning itself for significant impact in the field.
U.S. Precision Medicine
U.S. Precision Medicine (USPM) is developing DH20931, an AI-accelerated drug candidate targeting CerS2 for cancer therapeutics. With demonstrated 85% tumor reduction in preclinical trials, DH20931 aims to revolutionize oncology treatment by selectively inducing apoptosis in cancer cells. The company operates in the $200 billion global oncology market and holds patent protection until 2044. USPM leverages a proprietary drug discovery approach enhanced by AI collaborations and strategic partnerships with research institutions to address unmet needs in cancer treatment, positioning itself for significant impact in the field.